Vapendavir is an investigational oral antiviral agent belonging to the benzisoxazole class, currently under development for the treatment of human rhinovirus (HRV) infections, particularly in patients… Read more
Vapendavir is an investigational oral antiviral agent belonging to the benzisoxazole class, currently under development for the treatment of human rhinovirus (HRV) infections, particularly in patients with chronic respiratory conditions such as asthma and COPD. By acting as a capsid binder, it targets the viral life cycle to inhibit replication and prevent viral entry into human cells. To support the rigorous analytical requirements of pharmaceutical development, this category provides a range of high-quality Vapendavir reference standards. These include precisely characterized impurities and stable isotope labelled compounds, which are critical for accurate impurity profiling, metabolic pathway identification, and method validation. Laboratories rely on these analytical tools to ensure rigorous quality control and to maintain compliance with established testing protocols throughout the drug development and manufacturing lifecycle.